Abstract
Community health systems (CHS) provide over 50% of cancer care in the US. Biomarker testing rates among patients with advanced Non-Squamous (NSQ) Non-Small Lung Cancer (NSCLC) patients at CHS are not widely published. This analysis describes testing rates for clinically relevant biomarkers within this population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
